NASDAQ:CRVS • US2210151005
Past quarterly earnings results for CORVUS PHARMACEUTICALS INC (CRVS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.12 | -0.14 | 11.83% | 80.00% | - | - | ||
| Q2 2025 | -0.10 | -0.14 | 29.87% | -150.00% | - | - | ||
| Q1 2025 | 0.21 | -0.12 | 273.30% | 275.00% | - | - | ||
| Q4 2024 | -0.18 | -0.12 | -47.55% | -28.57% | - | - | ||
| Q3 2024 | -0.60 | -0.12 | -404.49% | -400.00% | - | - | ||
| Q2 2024 | -0.04 | -0.12 | 65.90% | 71.43% | - | - | ||
| Q1 2024 | -0.12 | -0.12 | 1.96% | 29.41% | - | - | ||
| Q4 2023 | -0.14 | -0.12 | -15.34% | 33.33% | - | - | ||
| Q3 2023 | -0.12 | -0.12 | 3.57% | 62.50% | - | - | ||
| Q2 2023 | -0.14 | -0.14 | 1.43% | 22.22% | - | - | ||
| Q1 2023 | -0.17 | -0.16 | -6.16% | 5.56% | - | - | ||
| Q4 2022 | -0.21 | -0.24 | 10.87% | -5.00% | - | - | ||
| Q3 2022 | -0.32 | -0.16 | -100.25% | -33.33% | - | - | ||
| Q2 2022 | -0.18 | -0.18 | 0.11% | 35.71% | - | - | ||
| Q1 2022 | -0.18 | -0.16 | -15.09% | 47.06% | - | - | ||
| Q4 2021 | -0.20 | -0.19 | -4.58% | 39.39% | - | - | ||
| Q3 2021 | -0.24 | -0.26 | 8.33% | 27.27% | - | - | ||
| Q2 2021 | -0.28 | -0.32 | 13.31% | 22.22% | - | - | ||
| Q1 2021 | -0.34 | -0.32 | -7.53% | 22.73% | - | - | ||
| Q4 2020 | -0.33 | -0.33 | -0.32% | - | - | - | ||
| Q3 2020 | -0.33 | -0.24 | -34.80% | - | - | - | ||
| Q2 2020 | -0.36 | -0.28 | -27.88% | - | - | - | ||
| Q1 2020 | -0.44 | -0.41 | -8.28% | - | - | - |
Notes
CORVUS PHARMACEUTICALS INC (CRVS) last reported earnings on 11/4/2025.
CORVUS PHARMACEUTICALS INC (CRVS) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CORVUS PHARMACEUTICALS INC (CRVS) has beaten EPS estimates in 3 out of 4 releases.